BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia (AML). This Orphan Drug designation is the second GVAX cancer vaccine [...]
BioSante Pharmaceuticals, Inc. announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer. Source: General Cancer News Articles Provided by Cancer Compass
EntreMed, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML). Source: General Cancer News Articles Provided by Cancer Compass